Security
Perceptive Capital Solutions Corp Class A Ordinary Shares · PCSC
PCSCNASDAQCommon stockHistorical · closed Jul 20, 2026CIK 2017526Updated Oct 30, 2026
Name history
Perceptive Capital Solutions Corp · through Jul 15, 2026
Current security for this SEC filerFRNM · NASDAQ
PCSC price & chart
Historical security
This listing closed Jul 20, 2026. Live provider charts are shown only for current listings.
Current security: FRNM
About the company
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company’s proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome’s development of SimpleScreen™ CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional indications is designed to increase cancer detection among millions of at-risk individuals. For more information, visit www.freenome.com.
In the news
Recent filings
Financials
FY 2025 · USDSource
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||
| AssetsUSD | 92,200,869Source | 89,006,823Source | 85,828,386Source | 91,402,832Source | 87,893,727Source | 93,329,160Source | 90,632,403Source | — | 92,779,988Source | 89,899,087Source |
| Current assets: | ||||||||||
| Assets, CurrentUSD | 1,263,122Source | 1,369,784Source | 742,154Source | 1,465,879Source | 1,434,298Source | 649,657Source | 1,343,493Source | — | 907,570Source | 1,244,690Source |
| LIABILITIES AND EQUITY | ||||||||||
| LiabilitiesUSD | 4,384,557Source | 3,609,979Source | 7,078,077Source | 3,731,154Source | 3,478,365Source | 6,305,165Source | 3,715,572Source | — | 5,704,244Source | 3,660,811Source |
| Stockholders’ equity: | ||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | 0Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -3,121,680Source | -1,940,440Source | -6,297,078Source | -2,265,520Source | -1,744,312Source | -5,655,753Source | -2,372,324Source | — | -4,796,919Source | -2,116,366Source |
| Stockholders' Equity Attributable to ParentUSD | -3,121,435Source | -1,940,195Source | -6,296,833Source | -2,265,275Source | -1,744,067Source | -5,655,508Source | -2,372,079Source | 9,603Source | -4,796,674Source | -2,116,121Source |
| Liabilities and EquityUSD | 92,200,869Source | 89,006,823Source | 85,828,386Source | 91,402,832Source | 87,893,727Source | 93,329,160Source | 90,632,403Source | — | 92,779,988Source | 89,899,087Source |
| Current liabilities: | ||||||||||
| Liabilities, CurrentUSD | 934,557Source | 159,979Source | 3,628,077Source | 281,154Source | 28,365Source | 2,855,165Source | 265,572Source | — | 2,254,244Source | 210,811Source |
| Additional Financial Items | ||||||||||
| Accrued Liabilities, CurrentUSD | 934,557Source | 159,979Source | 3,628,077Source | 281,154Source | 28,365Source | 2,855,165Source | 265,572Source | — | 2,254,244Source | 210,811Source |
cash flow · annual statements
| Line item | Q4 2025 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | -196,326Source | -297,852Source | -237,747Source | -864,653Source | — |
| Cash flows from investing activities: | ||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | -86,250,000Source | 0Source | 300,000Source | 600,000Source | — |
| Cash flows from financing activities: | ||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | 87,733,307Source | — | — | 0Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 1,177,909Source | 1,209,453Source | 437,369Source | 1,344,409Source | 1,286,981Source | 567,179Source | 1,191,937Source | 865,031Source | 1,129,684Source |
| Additional Financial Items | ||||||||||
| General and Administrative ExpenseUSD | — | — | — | 941,325Source | 193,196Source | — | — | — | 2,980,553Source | — |
| Investment Income, InterestUSD | — | 972,598Source | 1,163,406Source | 339,769Source | 948,922Source | 202,332Source | 841,181Source | 961,912Source | 3,821,319Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | 144,634Source | 981,482Source | -114,943Source | 754,847Source | 102,875Source | -51,749Source | 678,555Source | 837,468Source | — |
| Nonoperating Income (Expense)USD | — | — | — | 826,382Source | 948,043Source | — | — | — | 3,818,021Source | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | -951Source | -879Source | — | — | — | -3,298Source | — |
| Gain (Loss) on Investments | — | —Source | —Source | — | —Source | —Source | —Source | —Source | — | — |
| Operating Expenses | — | —Source | —Source | — | —Source | —Source | —Source | —Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | -856,160Source | -196,128Source | -941,325Source | -193,196Source | -106,554Source | -858,834Source | -255,958Source | -2,980,553Source |
| Net Income (Loss) Attributable to ParentUSD | — | 144,634Source | 981,482Source | -114,943Source | 754,847Source | 102,875Source | -51,749Source | 678,555Source | 837,468Source |
| Additional Financial Items | |||||||||
| General and Administrative ExpenseUSD | — | — | — | 941,325Source | 193,196Source | — | — | — | 2,980,553Source |
| Investment Income, InterestUSD | — | 972,598Source | 1,163,406Source | 339,769Source | 948,922Source | 202,332Source | 841,181Source | 961,912Source | 3,821,319Source |
| Nonoperating Income (Expense)USD | — | — | — | 826,382Source | 948,043Source | — | — | — | 3,818,021Source |
| Gain (Loss) on Investments | — | —Source | —Source | — | —Source | —Source | —Source | —Source | — |
| Operating Expenses | — | —Source | —Source | — | —Source | —Source | —Source | —Source | — |
Offerings
Registration 333-298423
Underwriters: Number of Shares, PIPE Investors(4), Pro Forma Common Stock Outstanding
Registration 333-295377
- Offering amount
- $240.0
- Offering price
- market-price
- Ticker
- PCSC
Registration 333-295377-01
- Offering amount
- $240.0
- Offering price
- market-price
- Ticker
- PCSC
Filing attachments
ef20084075_ex99-1.htm · 8-K · 2026-10-20
Exhibit 99.1 Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option - Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw - - In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and a 99.8% negative predictive value for lung cancer in its intended use population - BRISBANE, Calif. (Oct. 20, 2026) - Freenome, …
Read attachment ↗ef20082631_ex107.htm · S-8 · 2026-09-23
Exhibit 107 CALCULATION OF FILING FEE TABLES S-8 (Form Type) Freenome, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Maximum Aggregate Fee Rate Amount of Registration Fee …
Read attachment ↗ny20080283_ex107.htm · S-1 · 2026-08-18
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-1 (Form Type) Freenome, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Notes Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Fee Rate Amount of Registration Fee …
Read attachment ↗ef20080133_ex99-1.htm · 8-K/A · 2026-08-13
EX-99.1 2 ef20080133_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FREENOME HOLDINGS, INC. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except shares and par value data) June 30, 2026 December 31, 2025 ──────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗ef20080133_ex99-2.htm · 8-K/A · 2026-08-13
EX-99.2 3 ef20080133_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of the financial condition and results of operations of Freenome Inc. (“New Freenome,”, “we,” “us,” and “our”) should be read in conjunction with our unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2026 and 2025, and the audited consolidated f…
Read attachment ↗ef20078829_ex99-1.htm · 8-K · 2026-07-27
EX-99.1 2 ef20078829_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S. - Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening - - Medicare coverage and American Cancer Society guidance support broader access to blood-based colorectal cancer screening - BRISBANE, Calif. and ABBOTT PARK, Ill. (July 27, 2026) - Freenome, Inc. (Nasdaq:…
Read attachment ↗